Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
PDL BIOPHARMA, INC. (PDLI)
Sector: Healthcare; Industry: Biotechnology

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2009-04-08 SANDMAN PAUL W Director Buy 10,000 $7.38 $73,822 No

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.